カレントテラピー　29-12　サンプル page 28/42

このページは カレントテラピー　29-12　サンプル の電子ブックに掲載されている28ページの概要です。
秒後に電子ブックの対象ページへ移動します。
「電子ブックを開く」をクリックすると今すぐ対象ページへ移動します。

概要：
特集●分子腫瘍マーカー―治療標的と経過指標として8）Pardanani A, Vannucchi AM, Passamonti F, et al：JAKinhibitor therapy for myelofibrosis：critical assessment ofvalue and limitations. Leukemia 25：218....

特集●分子腫瘍マーカー―治療標的と経過指標として8）Pardanani A, Vannucchi AM, Passamonti F, et al：JAKinhibitor therapy for myelofibrosis：critical assessment ofvalue and limitations. Leukemia 25：218-225, 20119）Hitoshi Y, Lin N, Payan DG, et al：The current status andthe future of JAK2 inhibitors for the treatment of myeloproliferativediseases. Int J Hematol 91：189 -200, 2010, Erratumin：Int J Hematol 91：555, 201010）Knoops L, Constantinescu SN：JAK inhibitors in myeloproliferativeneoplasms. Belg J Hematol 2：27-35, 201111）Verstovsek S, Kantarjian H, Mesa RA, et al：Safety and efficacyof INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis.N Engl J Med 363：1117 -1127, 201012）Pardanani A, Gotlib JR, Jamieson C, et al：Safety and efficacyof TG101348, a selective JAK2 inhibitor, in myelofibrosis. JClin Oncol 29：789 -796, 201113）Tyner JW, Bumm TG, Deininger J, et al：CYT387, a novelJAK2 inhibitor, induces hematologic responses and normalizesinflammatory cytokines in murine myeloproliferative neoplasms.Blood 115：5232-5240, 201014）Hart S, Goh KC, Novotny-Diermayr V, et al：SB1518, a novelmacrocyclic pyrimidine -based JAK2 inhibitor for the treatmentof myeloid and lymphoid malignancies. Leukemia 148.（Epub ahead of print）15）Santos FP, Kantarjian HM, Jain N, et al：Phase 2 study ofCEP -701, an orally available JAK2 inhibitor, in patients withprimary or post -polycythemia vera/essential thrombocythemiamyelofibrosis. Blood 115：1131-1136, 201016）Scuto A, Krejci P, Popplewell L, et al：The novel JAK inhibitorAZD1480 blocks STAT3 and FGFR3 signaling, resultingin suppression of human myeloma cell growth and survival.Leukemia 25：538 -550, 201117）Ma L, Zhao B, Walgren R, et al：Efficacy of LY2784544, aSmall Molecule Inhibitor Selective for Mutant JAK2 Kinase,In JAK2 V617F -Induced Hematologic Malignancy Models.Poster 5054, 53 rd ASH annual meeting, Orlando, FL, U.S.A.201018）Shide K, Kameda T, Markovtsov V, et al：R723, a selectiveJAK2 inhibitor, effectively treats JAK2V617F -inducedmurine myeloproliferative neoplasm. Blood 117：6866-6875,201119）Tefferi A：JAK2 Inhibitor Therapy and Mechanisms ofResponse. SCI -36, 53 rd ASH annual meeting, Orlando, FL,U.S.A. 201020）Leber B, Geng F, Kale J, et al：Drugs targeting Bcl -2 familymembers as an emerging strategy in cancer. Expert Rev MolMed 12：e28, 201021）Bendall SC, Simonds EF, Qiu P, et al：Single -cell masscytometry of differential immune and drug responses acrossa human hematopoietic continuum. Science 332：687-696,2011Current Therapy 2011 Vol.29 No.12 751143